HPV Vaccine Session

Janet Gilsdorf, MD HPV Vaccine Workgroup Chair

ACIP Meeting February 22, 2007

ACIP HPV Vaccine Workgroup Activities

- Review data from clinical trials
- Review new epidemiology data
- Consider additional modeling and cost effectiveness analyses

GSK announced they will file with FDA in April 2007

- Develop recommendations options for use of bivalent HPV 16/18 vaccine for ACIP consideration
- Update ACIP statement to include bivalent HPV vaccine, when licensed

Proposed Schedule for Upcoming ACIP Meetings

- June 2007
 - Bivalent HPV vaccine Phase III data

- October 2007
 - Options for bivalent HPV vaccine recommendations

HPV Vaccine Session Presentations

- Quadrivalent HPV vaccine (Merck)
 - Phase III trials; follow-up efficacy data
- Bivalent HPV vaccine (GSK)
 - Phase II efficacy trials
 - Immunogenicity data in women >25 years
- Update on HPV vaccine
 - Distribution, safety, monitoring, etc